Angiotensin II Blockade for Chronic Allograft Nephropathy
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Chronic allograft nephropathy continues to be a major cause of kidney transplant loss and
return to dialysis. Treatment options are limited and the course of the disease tends to be
progressive. This trial is designed to prevent a major mediator of this process, namely the
expansion of the cortical interstitial compartment of the kidney where most of the scarring
occurs. The drug being studied, Losartan, has proven efficacious in a number of kidney
diseases.
Phase:
Phase 4
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute
Collaborators:
Merck Sharp & Dohme Corp. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)